Pearl River Capital’s United Therapeutics UTHR Stock Holding History

Pearl River Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,378	Closed	-$1.47M	–	634
2024 Q1	$1.47M	Sell	6,378 -1,630	-20%	-$368K	0.23%	144
2023 Q4	$1.76M	Buy	8,008 +2,780	+53%	+$641K	0.28%	101
2023 Q3	$1.18M	Sell	5,228 -31	-0.6%	-$7.14K	0.19%	186
2023 Q2	$1.16M	Sell	5,259 -2,437	-32%	-$540K	0.19%	173
2023 Q1	$1.72M	Buy	7,696 +5,039	+190%	+$1.24M	0.27%	115
2022 Q4	$739K	Buy	+2,657	New	+$671K	0.13%	253
2022 Q3	–	Sell	-1,456	Closed	-$343K	–	564
2022 Q2	$343K	Buy	+1,456	New	+$296K	0.08%	327
2021 Q4	–	Sell	-1,147	Closed	-$212K	–	577
2021 Q3	$212K	Sell	1,147 -500	-30%	-$98.5K	0.06%	368
2021 Q2	$295K	Buy	+1,647	New	+$314K	0.08%	325
2019 Q3	–	Sell	-407	Closed	-$32K	–	540
2019 Q2	$32K	Buy	+407	New	+$38.1K	0.2%	158

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pearl River Capital's UTHR Position: Q2 2024 in Review

Pearl River Capital sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 6,378 shares — an estimated $1.47M sold.

Pearl River Capital first reported a position in UTHR in Q2 2019 and held it in 10 quarters. The position peaked at $1.76M in Q4 2023. 568 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

Pearl River Capital reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
Pearl River Capital sold 6,378 United Therapeutics shares in Q2 2024, an estimated $1.47M.
Pearl River Capital first reported a position in United Therapeutics in Q2 2019 and held it in 10 quarters.
Pearl River Capital's United Therapeutics position peaked at $1.76M in Q4 2023.
568 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.